LC
BCAX

Lindbrook Capital’s Bicara Therapeutics BCAX Stock Holding History

Lindbrook Capital’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$925 Buy
+71
New +$943 ﹤0.01% 2479

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lindbrook Capital's BCAX Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Bicara Therapeutics (BCAX) in Q1 2025: 71 shares worth $925. The stake represents ﹤0.01% of the portfolio and ranks #2479 among its holdings.

93 funds tracked by Wall St. Rank hold BCAX as of Q1 2025.

  • Lindbrook Capital held 71 shares of Bicara Therapeutics worth $925 as of Q1 2025.
  • Bicara Therapeutics was a new Lindbrook Capital position in Q1 2025.
  • Bicara Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2479 holding.
  • 93 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.